Ocata Therapeutics Inc fka OCAT

[rocky301]

Ridda,


With regards to ACT holding off for that long so they can run trials in parallel doesn't make any logical sense to me and I can think of no major benefit in doing so, jmo. ACT has said the following many times:

The SMD was chosen to be first in trial because:
(stated by ACT)
a)Highest likelihood of seeing signal in Phase I
b)Significance of Market Exclusivity: Barrier to Entry
c)The only practical choice for first clinical trial involving
RPE cells for macular degeneration.

Also, it would be a different line of thinking for me if the SMD IRB protocol was approved but it is not and sounds like it may be a while.

Non-dilutive funding? Ridda, they have plenty of cash to move forward with SMD and if non-dilutive funding comes in later then apply it but I can't imagine ACT holding back on starting for that reason especially when you are talking about many months on delay.
I have no doubt a reason exists for the delay but I don't see either of those issues being the cause.jmo